Phase I/II trial of Amrubicin Hydrochloride in 3rd line treatment for patients with Recurrent Non-small cell Lung cancer [AMNOL-3rd]
Not Applicable
- Conditions
- Previously treated non-small cell lung cancer
- Registration Number
- JPRN-UMIN000000726
- Lead Sponsor
- Keio University School of Medicine Division of Pulmonary Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
The exclusion criteria consisted of pulmonary fibrosis or interstitial pneumonitis with symptoms or apparent abnormalities on chest X-ray, massive pleural effusion, pericardial effusion, or ascites, pregnancy, lactation, symptomatic brain metastases, active concurrent malignancies, severe drug allergies, myocardial infarction, severe heart disease, or severe infection. Patients who have already received amrubicin and other anthracycline drugs were excluded, too.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method